# Elucidating the Critical Role of Low-Density Lipoprotein Receptor Class A Domain Containing 3 in Venezuelan Equine Encephalitis Virus Neuron Infection and Pathogenesis

> **NIH NIH F30** · WASHINGTON UNIVERSITY · 2022 · $32,686

## Abstract

PROJECT SUMMARY
Alphaviruses are enveloped positive-stranded RNA viruses of the Togaviridae family whose natural endemic
cycles occur between mosquito vectors and nonhuman mammal or avian species. Venezuelan equine
encephalitis virus (VEEV) is an encephalitic alphavirus responsible for periodic epidemics in equine and human
populations across the Americas. Its potential for use as an aerosolized bioterrorism weapon and the
demonstrated risk it poses in research settings highlight the need for countermeasures. VEEV pathogenesis is
characterized by central nervous system (CNS) involvement and damage to lymphoid tissues. Our laboratory
published the discovery of a novel receptor for VEEV, low-density lipoprotein receptor class A domain containing
3 (LDLRAD3), required for infection and VEEV pathogenesis in vivo. We have demonstrated that a soluble fusion
protein with LDLRAD3 linked to an IgG Fc domain (LDLRAD3-Fc) protects mice from lethal infection. Though
this shows that identification of an entry receptor can become a target for countermeasures against VEEV, the
role of LDLRAD3 in controlling VEEV pathogenesis is still not understood. The first Aim of my proposal will
explore LDLRAD3-mediated tropism and neuroinvasion of VEEV. I hypothesize that LDLRAD3 is required for
VEEV infection of myeloid cells in peripheral organs and neurons in the central nervous system, which contribute
to the development of inflammation and clinical disease. This hypothesis will be tested using in vivo infection
studies that analyze viral RNA levels, histopathology, and virus tropism during time courses of infection in
Ldlrad3-/- mice. Cell-type specificity of LDLRAD3-mediated VEEV infection will be explored using mixed primary
neuron cultures from Ldlrad3-/- mice and tissue-specific conditional Ldlrad3-/- mice. Though the molecular
mechanisms of VEEV attachment and entry into host cells during infection are still poorly understood, recently
the interaction residues on VEEV have been identified for LDLRAD3 by cryo-electron microscopy. My second
Aim will determine which of these contact sites are of functional importance for VEEV infection in vitro and in
vivo. Using structure-guided mutagenesis, I will generate VEEV strains encoding mutations at LDLRAD3
interaction sites. These will be tested for altered infection using cell-based assays and differences in
pathogenesis using a lethal murine VEEV model. Mutations at LDLRAD3 interaction sites which result in
increased VEEV infectivity or binding will be engineered into a LDLRAD3-Fc decoy receptor to optimize its anti-
VEEV therapeutic function. Overall, these studies will define how LDLRAD3-dependent tropism of VEEV is
critical for the development of clinical disease and what key viral interaction residues required for binding of
VEEV to LDLRAD3 might be harnessed for the development of targeted antiviral therapies.

## Key facts

- **NIH application ID:** 10536362
- **Project number:** 1F30AI164842-01A1
- **Recipient organization:** WASHINGTON UNIVERSITY
- **Principal Investigator:** Natasha Monir Kafai
- **Activity code:** F30 (R01, R21, SBIR, etc.)
- **Funding institute:** NIH
- **Fiscal year:** 2022
- **Award amount:** $32,686
- **Award type:** 1
- **Project period:** 2022-08-01 → 2024-07-31

## Primary source

NIH RePORTER: https://reporter.nih.gov/project-details/10536362

## Citation

> US National Institutes of Health, RePORTER application 10536362, Elucidating the Critical Role of Low-Density Lipoprotein Receptor Class A Domain Containing 3 in Venezuelan Equine Encephalitis Virus Neuron Infection and Pathogenesis (1F30AI164842-01A1). Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/grant/nih/10536362. Licensed CC0.

---

*[NIH grants dataset](/datasets/nih-grants) · CC0 1.0*
